QuidelOrthoQDEL
QDEL
About: QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Employees: 6,600
0
Funds holding %
of 7,428 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
36% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $10.5M
24% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 79
6.27% more ownership
Funds ownership: 110.98% [Q1] → 117.25% (+6.27%) [Q2]
4% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 47
2% less funds holding
Funds holding: 264 [Q1] → 259 (-5) [Q2]
13% less capital invested
Capital invested by funds: $2.61B [Q1] → $2.28B (-$331M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 3 (-3) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
6%
downside
Avg. target
$33
19%
upside
High target
$40
45%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
UBS Lu Li | 6%downside $26 | Neutral Maintained | 7 Aug 2025 |
Citigroup Patrick Donnelly | 45%upside $40 | Buy Maintained | 6 Aug 2025 |
Financial journalist opinion
Based on 11 articles about QDEL published over the past 30 days
Neutral
PRNewsWire
4 days ago
QuidelOrtho Completes Debt Refinancing
SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.
Neutral
PRNewsWire
4 days ago
Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities
SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family Medicine and Community Health at the University of Wisconsin-Madison. In this 50th episode of QuidelOrtho Science Bytes, Dr. Temte outlines the seasonal challenges posed by influenza, RSV, COVID-19 and vaccine-preventable diseases such as measles and whooping cough.
Neutral
PRNewsWire
6 days ago
QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development
SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr.
Neutral
PRNewsWire
1 week ago
QuidelOrtho Launches Certified Analyzer Program
Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost.
Positive
Zacks Investment Research
2 weeks ago
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
2 weeks ago
Should Value Investors Buy QuidelOrtho (QDEL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
2 weeks ago
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand
QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.
Neutral
Seeking Alpha
2 weeks ago
QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Brian J. Blaser - President, CEO & Director Joseph M.
Neutral
The Motley Fool
2 weeks ago
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
Neutral
PRNewsWire
2 weeks ago
QuidelOrtho Reports Second Quarter 2025 Financial Results
― Labs revenue grew 4% as reported and 5% in constant currency ― ― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $614 million, as reported Non-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currency Labs revenue grew 4% as reported and 5% in constant currency Immunohematology revenue grew 4% as reported and 3% in constant currency Respiratory revenue was $47 million, a 20% decrease primarily driven by lower COVID-19 revenue GAAP and non-GAAP operating expenses1 decreased 9%, driven by the Company's cost-savings initiatives GAAP net loss margin was (42%); GAAP operating margin was (29%); adjusted EBITDA margin was 17%, a 330 basis point improvement GAAP diluted loss per share was $3.77; adjusted diluted earnings per share ("EPS") was $0.12 SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the second quarter ended June 29, 2025. "Our second quarter results demonstrate our continuing commitment to commercial and operational execution," said Brian J.
Charts implemented using Lightweight Charts™